Matching-Adjusted Indirect Comparison of Risankizumab Versus Icotrokinra in Adult Patients with Moderate-to-Severe Plaque Psoriasis - Takeaways - MDSpire

Matching-Adjusted Indirect Comparison of Risankizumab Versus Icotrokinra in Adult Patients with Moderate-to-Severe Plaque Psoriasis

  • By

  • Jeffrey Crowley

  • Eingun James Song

  • Linda Stein-Gold

  • Paolo Gisondi

  • Christopher G. Bunick

  • Vishvas Garg

  • Emanuele Leoncini

  • Blair Kaplan

  • Richard Ta

  • Bang Truong

  • Dolly Sharma

  • Bruce Strober

  • July 2, 2026

  • 0 min

Share

  • 1

    Risankizumab (RZB) is an IL-23 inhibitor approved for moderate-to-severe psoriasis, while icotrokinra (ICO) is a recently approved IL-23 receptor blocker.

  • 2

    Indirect comparisons between RZB and ICO are necessary to guide therapy selection due to the lack of head-to-head studies.

  • 3

    RZB showed a significantly higher proportion of patients achieving PASI 75, PASI 90, PASI 100, and IGA 0/1 compared to ICO at various time points.

  • 4

    The matching-adjusted indirect comparison suggests that RZB may provide greater clinical efficacy than ICO over a 52-week period.

  • 5

    The study utilized individual patient data from phase 3 trials to conduct a matching-adjusted indirect comparison of RZB and ICO.

Original Source(s)

Matching-Adjusted Indirect Comparison of Risankizumab Versus Icotrokinra in Adult Patients with Moderate-to-Severe Plaque Psoriasis

  • by Jeffrey Crowley, Eingun James Song, Linda Stein-Gold, Paolo Gisondi, Christopher G. Bunick, Vishvas Garg, Emanuele Leoncini, Blair Kaplan, Richard Ta, Bang Truong, Dolly Sharma, Bruce Strober

  • July 2, 2026

Related Content

The role of protein lactylation in skin diseases: from molecular mechanisms to potential therapeutics

Paradoxical inflammatory switches during biologic therapy: a mechanistic framework, clinical algorithm, and pediatric illustrations

Integrated systems toxicology identifies TCDD-responsive targets linked to immune dysregulation and treatment response in psoriasis